Content uploaded by Ayo Oginni
Author content
All content in this area was uploaded by Ayo Oginni on May 22, 2014
Content may be subject to copyright.
1 23
Maternal and Child Health Journal
ISSN 1092-7875
Volume 17
Number 7
Matern Child Health J (2013)
17:1191-1198
DOI 10.1007/s10995-012-1105-9
Maternal and Fetal Outcomes After
Introduction of Magnesium Sulphate for
Treatment of Preeclampsia and Eclampsia
in Selected Secondary Facilities: A Low-
Cost Intervention
Jamilu Tukur, Babatunde Ahonsi, Salisu
Mohammed Ishaku, Idowu Araoyinbo,
Ekechi Okereke & Ayodeji Oginni
Babatunde
1 23
Your article is protected by copyright and
all rights are held exclusively by Springer
Science+Business Media, LLC. This e-offprint
is for personal use only and shall not be self-
archived in electronic repositories. If you wish
to self-archive your article, please use the
accepted manuscript version for posting on
your own website. You may further deposit
the accepted manuscript version in any
repository, provided it is only made publicly
available 12 months after official publication
or later and provided acknowledgement is
given to the original source of publication
and a link is inserted to the published article
on Springer's website. The link must be
accompanied by the following text: "The final
publication is available at link.springer.com”.
Maternal and Fetal Outcomes After Introduction of Magnesium
Sulphate for Treatment of Preeclampsia and Eclampsia
in Selected Secondary Facilities: A Low-Cost Intervention
Jamilu Tukur •Babatunde Ahonsi •
Salisu Mohammed Ishaku •Idowu Araoyinbo •
Ekechi Okereke •Ayodeji Oginni Babatunde
Published online: 7 September 2012
ÓSpringer Science+Business Media, LLC 2012
Abstract The aim of this study was to evaluate whether a
new low-cost strategy for the introduction of magnesium
sulphate (MgSO
4
) for preeclampsia and eclampsia in low-
resource areas will result in improved maternal and perinatal
outcomes. Doctors and midwives from ten hospitals in Kano,
Nigeria, were trained onthe use of MgSO
4
. The trained health
workers later conducted step-down trainings at their health
facilities. MgSO
4
, treatment protocol, patella hammer, and
calcium gluconate were then supplied to the hospitals. Data
was collected through structured data forms. The data was
analyzed using SPSS software. From February 2008 to Jan-
uary 2009, 1,045 patients with severe preeclampsia and
eclampsia were treated. The case fatality rate for severe pre-
eclampsia and eclampsia fell from 20.9 % (95 % CI
18.7–23.2) to 2.3 % (95 % CI 1.5–3.5). The perinatal mor-
tality rate was 12.3 % as compared to 35.3 % in a center using
diazepam. Introductionof MgSO
4
in low-resource settings led
to improved maternal and fetal outcomes in patients present-
ing with severe pre-eclampsia and eclampsia. Training of
health workers on updated evidence-based interventions and
providing an enabling environment for their practice are
important components to the attainment of the Millenium
Development Goals (MDG) in developing countries.
Keywords Severe preeclampsia Eclampsia
Maternal mortality Millennium development goals
Magnesium sulphate
Introduction
As we approach 2015, there are several efforts at achieving
the Millennium Development Goals (MDG). The 4th MDG
is to reduce child mortality in children under 5 years old by
two-thirds while the 5th is to reduce maternal deaths by
75 % between 1990 and 2015 [1].
An area that has attracted attention is hypertensive dis-
orders of pregnancy. Ten percent of women have high
blood pressure during pregnancy, and preeclampsia com-
plicates 2–8 % of pregnancies. Ten to fifteen percent of
direct maternal deaths are associated with preeclampsia
and eclampsia [2]. The World Health Organization (WHO)
estimates that at least 16 % of maternal deaths in low- and
middle-income countries result from the hypertensive dis-
orders of pregnancy, of which eclampsia is the primary
contributor [3].
Based upon the Eclampsia Trial Collaborative Group in
1995, the World Health Organization (WHO) recommends
Magnesium sulphate (MgSO
4
) for the treatment of severe
preeclampsia and eclampsia (SPE/E). The eclampsia trial
collaborative study compared regimens for treatment of
eclamptic seizures. Women treated with MgSO
4
had 52
and 67 % lowered risk of recurrent seizures compared to
women who were treated with diazepam and phenytoin,
respectively. Maternal mortality was non-significantly
lowered in the women who received MgSO
4
[4].
Despite the evidence of its effectiveness, the use of
MgSO
4
has remained low especially in developing coun-
tries where it is incidentally needed the most [5].
Some of the reasons for the low availability and utili-
zation of MgSO
4
include the lack of guidelines on its use,
non-inclusion in many national essential drug lists, the
wrong perception that the drug is meant for use only at the
highest level of facilities (such as those with intensive-care
J. Tukur (&)
Department of Obstetrics and Gynaecology, Bayero University/
Aminu Kano Teaching Hospital, Kano, Nigeria
e-mail: jtukur@yahoo.com
B. Ahonsi S. Mohammed Ishaku I. Araoyinbo
E. Okereke A. O. Babatunde
Population Council, Abuja, Nigeria
123
Matern Child Health J (2013) 17:1191–1198
DOI 10.1007/s10995-012-1105-9
Author's personal copy
facilities), lack of training of health workers on its use,
little incentive for pharmaceutical companies to commer-
cialize the drug, and ready availability of pre-packaged
forms of less effective drugs [5,6]. Other identified barriers
include a lack of procurement from governments, a lack of
demand by health workers, and lack of in-service training
on the use of MgSO
4
[7]. There has been a call by the
WHO for the evidence on MgSO
4
’s efficacy to be dis-
seminated, the drug to be registered and made available in
all countries, the World Bank and other charitable orga-
nizations to fund the provision and distribution of treatment
kits and other international organizations to assist on
training frontline clinicians on how to use the drug [8].
Study Setting
Nigeria is located in West Africa and is Africa’s most
populous nation with a population of 162.5 million people
[9]. The Nigerian Health system divides hospitals into
primary, secondary, and tertiary hospitals with referral
linkages between them. Patients with SPE/E are referred
from primary to secondary and tertiary health facilities for
management. Delays are common due to lack of transport,
bad roads, and sometimes lack of knowledge from the
patient and relations on the seriousness of the condition. In
addition, there is poor record-keeping of births, as they are
kept only at hospitals even though the NDHS showed that
only 35 % of deliveries take place in hospitals [10]. As
registration of births and deaths in the community are not
compulsory, health facility-based data are often all that is
available for research.
In addition, the federal system of government being
practiced in Nigeria divides levels of governance into three
distinct and independent entities, which are federal, state,
and local governments. Consequently, the health care
system is disintegrated along this model with tertiary
institutions being managed by the federal government,
secondary institutions by the state governments, and pri-
mary health care by the local government authorities, with
no formal connection between these levels of care [11]. As
a result, the care for pre-eclampsia and eclampsia, as for
other major obstetric emergencies, is not properly coordi-
nated across these levels of service delivery. Furthermore,
the guideline of the Federal Ministry of Health in Nigeria
for managing eclampsia excludes lower-cadre service
providers in the management of the condition.
Nigeria has a high maternal mortality rate of 545 per
100,000 live births [10] with eclampsia as a major con-
tributor. Studies in northern Nigeria showed that eclampsia
contributed 31.3, 46.4, and 43.1 % of all maternal deaths in
Kano [12], Nguru [13], and Birnin Kudu [14], respectively.
In contrast, eclampsia contributed 34.4 % of maternal
deaths in Enugu in southern Nigeria [15]. The differences
in the contribution of eclampsia to maternal deaths could
be due to the culture of early marriage in northern Nigeria
and also delays in accessing care.
Kano is one of the states in the northwest of Nigeria.
The last Nigerian National census showed Kano as being
the most populous state in the country with a population of
9,401,288 [9]. Kano has a maternal mortality ratio (MMR)
of over 1,000 per 100,000 and a relatively high total fer-
tility rate of over seven births per woman, with 45 % of
adolescents aged 15–19 having already begun childbearing
and a modern contraceptive prevalence rate of less than
5%[10]. Kano state has 35 general hospitals, offering free
maternity care funded by the government.
In 2007, the Population Council secured funding from
the MacArthur Foundation for the project. This followed a
baseline survey that showed that the drug used for the
treatment of SPE/E in all the 35 general hospitals was
diazepam. The survey also reviewed data from three gen-
eral hospitals (Bichi, Wudil, and MMSH) to determine the
contribution of SPE/E to maternal deaths and its case
fatality rate prior to the introduction of MgSO
4
. The
baseline survey data covered the period January 1, 2007 to
December 31, 2007.
Materials and Methods
The data collection for the project started on February 1,
2008 and ended on January 31, 2009. In January 2008, one
doctor and one midwife from each of ten selected general
hospitals were invited to Kano, the state capital for train-
ing. The hospitals were selected on the basis of geographic
spread across the state, population, and high burden of
maternal deaths. The hospitals were at Kano, Bichi, Wudil,
Gwarzo, Rano, Minjibir, Tudun Wada, Doguwa, Rano, and
Rogo. Apart from Kano, the rest were rural towns. Also
invited for the training were five officials of the Hospitals
Management Board.
The facilities were spread across the entire state with
Kano metropolis at the center. The distance from each
facility to Kano where advanced life support exists ranges
from 42 km (Wudil) to 165 km (Doguwa), but since these
facilities receive referral from their surrounding clustered
primary health care (PHC) facilities, the average distance
from a particular PHC to its referral facility ranges from 15
to 30 km.
For this study, a pregnant woman was defined as having
pre-eclampsia if she had high blood pressure in the second
half of pregnancy of 140 mmHg systolic or more and/or
diastolic blood pressure of 90 mmHg or more with pro-
teinuria (at least 2?of proteinuria using urine dipstick).
Features of severe preeclampsia included features of
1192 Matern Child Health J (2013) 17:1191–1198
123
Author's personal copy
preeclampsia and symptoms of headache, blurring of
vision, vomiting and/or epigastric pain. Most of the hos-
pitals did not have adequate laboratory facilities to enable
us to use laboratory markers to define severity. Any woman
who fitted and had features of preeclampsia was defined as
having eclampsia. However, across all the centers, severe
preeclampsia and eclampsia were treated similarly. This
involved administration of MgSO
4
, administration of
hydralazine (where the diastolic blood pressure was
110 mmHg or more), fluid management and then the
delivery of the patient through the fastest route. The latter
involves a Cesarean section where the woman was not in
labor and augmentation with oxytocin where the woman
was already in labor.
Two sets of trainings were conducted for the providers.
The first was the ‘‘Training of Trainers’’ (ToT) during
which 25 trainers were trained on the use of MgSO
4
. The
second was the step-down training conducted by the master
trainers at their respective health facilities. Both trainings
were similar.
The training was conducted over 2 days. The first day
involved didactic lectures on evidence-based management
of hypertensive disorders of pregnancy and how to use
MgSO
4
including the detection and treatment of toxicity.
The participants were taught how to use MgSO
4
by the
intramuscular (IM) route. For the purpose of the training,
the dose used was a loading dose of 4 g administered
intravenously followed by 10 g administered IM (5 g in
each buttock). This was followed by 5 g administered IM
every 6 h until 24 h after delivery or the last seizure.
Monitoring of toxicity was done by checking the deep
tendon knee reflex before administering each dose of
MgSO
4
.
To aid the training, a simple clinical protocol was distrib-
uted to the participants. The second day was used for a prac-
tical training at the 25-bed eclamptic ward of MMSH. There
was a demonstration of the use of sphygmomanometer to
detect hypertension and urinalysis for proteinuria. The par-
ticipants practiced preparation of different dosages of mag-
nesium sulphate and monitoring for toxicity. At the end of the
training, the participants were supplied the initial stock of
MgSO
4
to take back to their hospitals, patella hammer (for
early detection of toxicity), and calcium gluconate (the anti-
dote for toxicity). The trained health workers returned to their
hospitals and conducted step-down trainings. All the facilities
commenced the use of the drug after the step down training.
Data was then obtained from the ten health facilities on the
maternal sociodemographic characteristics, pattern of SPE/E,
and the fetomaternal outcomes. The data was obtained by
filling of structured forms by the attending health workers.
Relevant information that was captured includes patients’
obstetrics demographic variables, fetal outcomes (dead or
alive) including APGAR score at 5 min, maternal outcomes
(dead or alive) including complications, number of seizures
before presentation, recurrence of seizures while on MgSO
4
,
distance traveled before presentation, time lapse from onset of
seizures to presentation at facility, mode of delivery and
complications of MgSO
4
administration. The forms were
collated monthly from the sites and analyzed at Kano. How-
ever, due to poor record keeping culture, obtaining high-
quality datawas a challenge and some data were missing. Data
review meetings were held monthly at all the sites to
encourage the health workers to fill the forms properly. The
data collection improved over time.
The data were summarized with frequencies and per-
centages. The associations between the dependent variables
(eclampsia CFR and infant perinatal mortality) and the
independent variables were measured with odds ratio
(95 % CI) using binary logistic regression. To obtain the
significant correlates of the dependent variables while
controlling for the effect of each independent variable,
multivariate analyses were also conducted using binary
logistic regression. The analyses were done with SPSS 15
for Windows (SPSS Inc., Chicago, IL, USA).
Results
The baseline survey involving three general hospitals
showed that there were a total of 1,233 patients with SPE/E
of whom 258 died giving a baseline CFR of 20.9 % (95 %
CI 18.7–23.2).
Twenty-five master trainers were trained at the initial
training of trainers at Kano. They then trained 160 health
workers (doctors, midwives, and community health
extension workers) through step-down trainings at the ten
health facilities. There was universal acceptance of the
change though few health workers resisted the change and
there were initial difficulties with calculation of doses.
These challenges improved with time.
During the period of the project, a total of 49 severe pre-
eclampsia and 996 eclamptic patients were treated at the
ten hospitals. There were 22,502 deliveries during the same
period. Table 1summarizes the socio-demographic char-
acteristics of the patients that had SPE/E. A majority
(51.5 %) of the patients were teenagers aged 15–19 years
old. About 60 % of the patients were primigravida and
more than two-thirds (74 %) had no formal education. All
the patients were married and the majority (71.0 %) were
in a monogamous relationship.
More than half (56.9 %) of the patients presented at the
health facilities in less than an hour of eclampsia episode,
while a few others (23.3 %) presented after 3 h or more. A
majority (81.2 %) of the patients had at least a seizure
before their presentation at the health facilities. Also, 584
(55.9 %) of the patients had antenatal care.
Matern Child Health J (2013) 17:1191–1198 1193
123
Author's personal copy
The commonest mode of delivery among the patients
was spontaneous vertex delivery (75.6 %), distantly fol-
lowed by caesarean section (16.8 %), assisted vaginal
deliveries (2.3 %) and some few missing data (5.3 %).
Table 2shows the fetomaternal outcomes. The CFR for
the patients treated with magnesium sulphate was 2.3 %
(95 % CI 1.5–3.5) as 24 of the 1,045 patients died. The
perinatal mortality was 12.3 % (CI 10.4–14.5) as 129 of the
1,045 mothers delivered dead babies. The 5-min APGAR
score for 72.9 % of the babies was 7 or more.
Further analysis was done to determine factors associ-
ated with maternal mortality, as shown in Table 3. The
significant measures of association showed that the CFR
was five times significantly higher among the patients with
parity of seven or more children than among the nullipa-
rous and six times higher among the patients that had
recurrent seizures after the loading dose than among the
patients that had none.
Factors associated with perinatal mortality are shown in
Table 4. Perinatal mortality was significantly higher among
the patients that had three or more seizures before pre-
sentation than among those that had no seizures at
presentation; the prevalence significantly increased with
increasing number of seizures before presentation. Simi-
larly, perinatal mortality was about three times higher
among the patients that had recurrent seizures after the
loading dose than among those who had no recurrent sei-
zures and four times higher among the patients that had
assisted breech delivery than those that had spontaneous
vaginal delivery.
Discussion
The case fatality rate for SPE/E was reduced from 20.9 %
(prior to the intervention) to 2.3 % (after the intervention).
This finding shows that MgSO
4
has a great role to play in the
reduction of maternal deaths. Reduction of deaths among
mothers treated with MgSO
4
compared to those treated with
diazepam has been reported from a center in southeastern
Nigeria [16]. Promoting, disseminating, and implementing
use of magnesium sulphate has been recognized as the most
important action to reduce maternal deaths from eclampsia
[17]. However, what is more important is that it was
Table 1 Socio-demographic characteristics of the patients that received MgSO
4
Basic characteristics Pre-eclampsia
(n=49)
Eclampsia Total
(n=1,045)
Antepartum
(n=322)
Intrapartum
(n=430)
Postpartum
(n=244)
(%) (%) (%) (%) (%)
Age (years)
15–19 19 (38.8) 161 (50.0) 254 (59.1) 104 (42.6) 538 (51.5)
20–24 19 (38.8) 94 (29.2) 137 (31.9) 81 (33.2) 331 (31.7)
25–48 10 (20.4) 62 (19.3) 35 (8.1) 51 (20.9) 158 (15.1)
Unknown 1 (2.0) 5 (1.6) 4 (0.9) 8 (3.3) 18 (1.7)
Parity
0 30 (61.2) 195 (60.6) 311 (72.3) 95 (38.9) 631 (60.4)
1–5 13 (26.5) 110 (34.2) 106 (24.7) 135 (55.3) 364 (34.8)
[5 6 (12.2) 15 (4.7) 11 (2.6) 7 (2.9) 39 (3.7)
Unknown 0 2 (0.6) 2 (0.5) 7 (2.9) 11 (1.1)
Educational status
None 36 (73.5) 237 (73.6) 311 (72.3) 190 (77.9) 77 (74.1)
Nursery 3 (6.1) 18 (5.6) 12 (2.8) 9 (3.7) 42 (4.0)
Primary 4 (8.2) 40 (12.4) 68 (15.8) 30 (12.3) 142 (13.6)
Secondary/vocational 4 (8.2) 24 (7.5) 23 (5.3) 12 (4.9) 63 (6.0)
Tertiary 1 (2.0) 2 (0.6) 2 (0.5) 0 5 (0.5)
Unknown 1 (2.0) 1 (0.3) 14 (3.3) 3 (1.2) 19 (1.8)
Marital status
Married
(monogamous)
37 (75.5) 222 (68.9) 315 (73.3) 168 (68.9) 742 (71.0)
Married (polygamous) 12 (24.5) 99 (30.7) 114 (26.5) 76 (31.1) 301 (28.8)
Unknown 0 1 (0.3) 1 (0.2) 0 2 (0.2)
1194 Matern Child Health J (2013) 17:1191–1198
123
Author's personal copy
introduced in an area where it was not previously available
and this can be replicated in other areas especially in
developing countries. This was a relatively easy intervention
involving training health workers and providing the neces-
sary tools for them to practice what they learned. Yet, it had a
huge impact in reducing maternal deaths. Introduction of
similar interventions in developing countries could help in
the attainment of the MDGs.
Despite the successful reduction in CFR for SPE/E,
there were several factors that were identified to be con-
tributory to the recorded deaths. Analysis of these factors
helps in further reducing maternal deaths. In this study,
most cases were seen in primigravida, especially teenagers.
This finding is similar to that from other studies [13,14].
This group of patients need to be targeted in any program
aimed at preventing SPE/E. Antenatal care is an opportu-
nity for detecting preeclampsia through monitoring of
blood pressure and detection of proteinuria. There is a need
to improve the quality of the antenatal care. It is a common
scenario in the hospitals under the study to observe one or
two nurses conducting antenatal care to 200–400 patients
in a single day. Task-shifting has been advocated to miti-
gate the lack of health workers. Tasks can be delegated to
non-physician clinicians, medical assistants, nurses, and
community health care workers [18].
To prevent eclampsia, it is necessary to first diagnose
pre-eclampsia using routine blood pressure and urine pro-
tein testing of all women [19]. Those that have pre-
eclampsia can then be treated with anti-hypertensives and
delivered early. Antenatal care also presents an opportunity
for instituting current evidence-based, possibly preventive,
strategies to those at risk in the form of low-dose aspirin
and calcium supplementation. Aspirin is associated with a
10–19 % reduction in pre-eclampsia risk and a 10–16 %
decrease in perinatal morbidity and mortality [20]. At least
1 g of calcium supplementation is also associated with
reduction in preeclampsia in those with low dietary cal-
cium [21]. There is also a need for community health
education on the importance of antenatal care.
The finding also that most of the patients with eclampsia
had at least a seizure at home means there is a need to
educate the patients on warning symptoms of eclampsia
such as headache, blurring of vision, and epigastric pain.
Among those that had eclampsia, more deaths were
recorded in those of high parity ([7) and those who had a
seizure after the loading dose. These groups of patients are
those in whom there could be other underlying pathologies
apart from eclampsia. These characteristics are those of
patients in whom a clinical search needs to be conducted
for other underlying causes for the seizures. In these cases,
however, this was not done, due to a lack of facilities.
The stillbirth rate in this study was 12.3 % (CI 10.4–14.5).
Unfortunately, there was no baseline perinatal mortality for
comparison. However, the finding is much lower than the
35.3 % stillbirth rate reported from another center using
diazepam [22], even though other studies show that mag-
nesium sulphate has no impact on stillbirth rates [23]. The
factors associated with perinatal mortality were recurrent
seizures fits after the loading dose, those delivered by
assisted breach delivery than among the patients that had
Table 2 Clinical outcomes of the pregnancies after the administration of the MgSO
4
Clinical outcomes Pre-eclampsia (n=49) Eclampsia Total (n=1,045)
Antepartum (n=322) Intrapartum (n=430) Postpartum (n=244)
(%) (%) (%) (%) (%)
Apgar score at 5 min
0 1 (0.2) 15 (4.7) 27 (6.3) 13 (5.3) 56 (5.4)
1–6 0 11 (3.4) 32 (7.4) 7 (2.9) 50 (4.8)
7 3 (6.1) 38 (11.8) 84 (19.5) 12 (4.9) 137 (13.1)
8 21 (42.9) 105 (32.6) 138 (32.1) 39 (16.0) 303 (29.0)
9 12 (24.5) 70 (21.7) 90 (20.9) 26 (10.7) 198 (18.9)
C10 3 (6.1) 26 (8.1) 32 (7.4) 63 (25.8) 124 (11.9)
Unknown 9 (18.4) 57 (17.7) 27 (6.3) 84 (34.4) 177 (16.9)
Fetal outcome
Dead 2 (4.1) 49 (15.2) 53 (12.3) 25 (10.2) 129 (12.3)
Alive 40 (81.6) 250 (77.6) 373 (86.7) 210 (86.1) 873 (83.5)
Unknown 7 (14.3) 23 (7.1) 4 (0.9) 9 (3.7) 43 (4.1)
Maternal outcome
Dead 1 (2.0) 9 (2.8) 8 (1.9) 6 (2.5) 24 (2.3)
Alive 43 (87.8) 289 (89.8) 420 (97.7) 231 (94.7) 983 (94.1)
Unknown 5 (10.2) 24 (7.5) 2 (0.5) 7 (2.9) 38 (3.6)
Matern Child Health J (2013) 17:1191–1198 1195
123
Author's personal copy
spontaneous vaginal delivery, and those that had seizures
before presentation. The first factor is also associated with
maternal deaths, which invariably affect the baby. Those
who had breech delivery had a higher mortality probably
because of the extra manipulation needed to deliver these
babies. Those mothers who had both breech presentation and
eclampsia were more likely to have an improved outcome
with a primary Cesarean delivery. The last factor implies
some delays from the mother before accessing care, in which
case the baby is invariably affected.
Table 3 Factors associated with eclampsia CFR
CFR (95 % CI) COR (95 % CI) AOR (95 % CI)
Age (years)
15–19 (ref) 1.5 (0.5, 2.6) 1.00 1.00
C20 3.4 (1.8, 5.1) 2.27 (0.96, 5.35) 1.46 (0.40, 5.42)
Parity
0 (ref) 1.6 (0.6, 2.6) 1.00 1.00
1–5 2.9 (1.1, 4.6) 1.79 (0.74, 4.35) 1.14 (0.31, 4.17)
C6 8.6 (0.8, 18.0) 5.66 (1.49, 21.59) 4.99 (0.77, 32.22)*
Marital status
Married, monogamous (ref) 1.7 (0.7, 2.6) 1.00 1.00
Married, polygamous 4.3 (1.9, 6.7) 2.67 (1.18, 6.01) 2.97 (0.82, 10.79)
Educational status
None (ref) 2.4 (1.3, 3.5) 1.00 1.00
Primary 2.9 (0.1, 5.7) 1.20 (0.40, 3.59) 1.18 (0.23, 6.23)
Secondary/higher 3.0 (1.1, 7.2) 1.26 (0.29, 5.55) 1.00 (0.12, 8.25)
Antenatal care
Attends (ref) 1.8 (0.7, 2.9) 1.00 1.00
Does not attend 3.3 (1.6, 5.1) 1.91 (0.84, 4.35) 0.57 (0.15, 2.13)
Number of fits before presentation
B2 (ref) 1.3 (0.3, 2.3) 1.00 1.00
C3 2.9 (1.3, 4.4) 2.26 (0.85, 6.01) 2.19 (0.63, 7.55)
Distance (km) traveled before presentation
\1 (ref) 2.1 (0.6, 3.5) 1.00 1.00
C1 2.2 (1.1, 3.3) 1.08 (0.45, 2.60) 0.26 (0.05, 1.33)
Time (h) before presentation
\1 (ref) 1.5 (0.5, 2.5) 1.00 1.00
C1 3.1 (1.4, 4.7) 2.10 (0.89, 4.96) 2.95 (0.63, 13.66)
Recurrent fits after administering the loading dose
No (ref) 1.8 (0.9, 2.6) 1.00 1.00
Yes 9.2 (2.1, 16.3) 5.54 (2.10, 14.58) 7.65 (1.62, 36.03)*
Mode of delivery
SVD 1.8 (0.9, 2.7) 0.78 (0.25, 2.39) 0.77 (0.19, 3.09)
CS (ref) 2.3 (0.1, 4.5) 1.00 1.00
AVD 4.2 (4.0, 12.3) 1.86 (0.20, 17.36) 2.58 (0.16, 41.52)
Condition
Pre-eclampsia (ref) 2.3 (2.2, 6.7) 1.00 1.00
Eclampsia 2.4 (1.4, 3.4) 1.05 (0.14, 7.97) 0.59 (0.04, 8.94)
Total ampoules of MgSO
4
received
B6 2.6 (0.3, 4.9) 1.87 (0.56, 6.22) 1.16 (0.18, 7.56)
7–17 3.0 (1.4, 4.6) 2.08 (0.78, 5.53) 1.13 (0.25, 5.01)
18 (ref) 1.5 (0.3, 2.7) 1.00 1.00
COR crude odds ratio, AOR adjusted odds ratio
* Significant at p\0.05
1196 Matern Child Health J (2013) 17:1191–1198
123
Author's personal copy
The limitation of this study is that of missing data which
arose from incorrectly filled forms or even failure to com-
plete the forms in some cases. Also, the study assumes that all
patients received the standard dosage of the drug as the health
workers were taught in the training. As the health workers
also fill the forms, our assumptions could be wrong. In
addition, the study was conducted in an area where women
prefer to deliver at home. It is possible that a majority of
women with this condition are not reflected in this study,
although there is a tendency that even such women will come
to the hospital when complications such as SPE/E develop.
In conclusion, this study clearly shows that the introduction
of magnesium sulphate usage for SPE/E using this low-cost
replicableintervention had a positive impact on both maternal
and fetal morbidity and mortality. The state government
should make the project sustainable on withdrawal of donor
support so that the patients can continue to reap the benefits.
Conflict of interest None declared.
References
1. United Nations. Millennium Development Goals. 2007 progress
report 2007, http://mdgs.un.org/unsd/mdg/default.aspx. Accessed
January 2011.
2. Duley, L. (2009). The global impact of pre-eclampsia and
eclampsia. Seminars in Perinatology, 33(3), 130–137.
3. Khan, K. S., Wojdyla, D., Say, L., et al. (2006). WHO analysis of
causes of maternal death: A systematic review. Lancet, 367,
1066–1074.
4. The Eclampsia Trial Collaborative Group. (1995). Which anti-
convulsant for women with eclampsia? Evidence from the col-
laborative eclampsia trial. Lancet, 345(8963), 1455–1463.
5. Tukur, J. (2009). The use of magnesium sulphate for the treat-
ment of severe pre-eclampsia and eclampsia. Annals of African
Medicine, 8, 76–80.
6. Langer, A., Viller, J., Tell, K., Kim, T., & Kennedy, S. (2008).
Reducing eclampsia related deaths: A call to action. Lancet, 371,
705–706.
7. Ridge, L. A., Bero, L. A., & Hill, R. S. (2010). Identifying bar-
riers to the availability and use of magnesium sulphate injection
in resource poor countries: A case study in Zambia. BioMedical
Central Health Services Research, 10, 340.
8. Sheith, S. S., & Chalmers, I. (2002). Magnesium for preventing
and treating eclampsia: Time for international action. Lancet,
359, 1872–1873.
9. National Population Commission. (2006). Population and hous-
ing census of the Federal Republic of Nigeria. Available from
http://www.population.gov.ng/images/stories/Priority%20Tables
%20Volume%20I-update.pdf (Accessed July 14th 2011).
10. National Population Commission (NPC) and ICF Macro. (2008).
Nigeria Demographic and Health Survey (NDHS).http://www.
measuredhs.com/pubs/pdf/GF15/GF15.pdf.
11. Kombe, G., Fleisher, L., Kariisa, E., Arur, A., Sanjana, P., &
Paina, L. et al. (April 2009). Nigeria health system assessment
2008. Abt Associates Inc.
Table 4 Factors associated with perinatal mortality
Factors Perinatal mortality % (95 % CI) Adjusted OR (95 % CI)
Marital status
Married monogamous 10.6 (8.6, 13.1) 1.00
Married polygamous 16.3 (12.4, 21.1) 1.17 (0.72, 1.92)
Antenatal care
Attends 10.1 (7.8, 12.9) 1.00
Does not attend 14.6 (11.5, 18.3) 0.88 0.55, 1.42)
Recurrent fits after MgSO
4
loading dose
No 11.4 (9.5, 13.6) 1.00
Yes 27.7 (17.3, 40.2) 2.64 (1.25, 5.54)*
Mode of delivery
CS 8.5 (4.8, 13.7) 1.00
SVD 12.4 (10.2, 15.0) 1.24 (0.65, 2.36)
ABD 29.2 (12.6, 51.1) 3.48 (1.12, 10.91)*
Number of fits before presentation
0 3.7 (1.0, 9.1) 1.00
1–2 10.4 (7.6, 14.1) 3.02 (0.90, 10.20)
3–4 13.4 (9.9, 17.9) 3.69 (1.09, 12.48)
C5 17.9 (12.4, 24.5) 5.70 (1.63, 19.93)*
Time before presentation (h)
\1 9.7 (7.5, 12.5) 1.00
C1 16.3 (13.0, 20.2) 1.04 (0.65, 1.68)
COR crude odds ratio, AOR adjusted odds ratio, CS Cesarean section, SVD spontaneous vaginal delivery, ABD assisted breech delivery
* Significant values at p\0.05
Matern Child Health J (2013) 17:1191–1198 1197
123
Author's personal copy
12. Adamu, Y. M., Salihu, H. M., Sathiakumar, N., & Alexander, R.
(2003). Maternal mortality in Northern Nigeria: A population
based study. European Journal of Obstetrics, Gynaecology and
Reproductive Biology, 109(2), 153–159.
13. Kullima, A. A., Kawuwa, M. B., Audu, B. M., Usman, H., &
Geidam, A. D. (2009). A 5-year review of maternal mortality
associated with eclampsia in a tertiary institution in northern
Nigeria. Annals of African Medicine, 8(2), 81–84.
14. Tukur, J., Umar, B. A., & Rabi’u, A. (2007). Pattern of eclampsia
in a tertiary health facility situated at a semi rural town in
Northern Nigeria. Annals of African Medicine, 6(4), 164–167.
15. Onakewhor, J. U., & Gharoro, E. P. (2008). Changing trends in
maternal mortality in a developing country. Nigerian Journal of
Clinical Practice, 11(2), 111–120.
16. Eke, A. C., Ezebialu, U. I., & Okafor, C. (2011). Presentation and
outcome of eclampsia at a tertiary center in South East Nigeria—
A 6-year review. Hypertension in Pregnancy, 30, 125–132.
17. Tsu, V. D., & Shane, B. (2004). New and underutilized tech-
nologies to reduce maternal mortality: Call to action from a
bellagio workshop. International Journal of Gynaecology and
Obstetrics, 85(Suppl 1), S83–S93.
18. Firoz, T. et al. (2011). Pre-eclampsia in low and middle income
countries. Best Practice & Research Clinical Obstetrics and
Gynaecology. doi:10.1016/j.bpobgyn.2011.04.002.
19. Goldenberg, R. L., McClure, E. M., McGuire, E. R., Kamath, B.
D., & Jobe, H. A. (2011). Lessons for low-income regions fol-
lowing the reduction in hypertension-related maternal mortality
in high-income countries. International Journal of Gynaecology
and Obstetrics, 113, 91–95.
20. Askie, L., Duley, L., Henderson-Smart, D., et al. (2007). Anti-
platelet agents for prevention of pre-eclampsia: A meta-analysis
of individual patient data. Lancet, 369, 1791–1798.
21. Hofmeyr, G. J., Atallah, A. N., & Duley, L. (2006). Calcium
supplementation during pregnancy for preventing hypertensive
disorders and related problems. Cochrane Database of Systematic
Reviews, CD001059.
22. Melah, G. S., Massah, A. A., & El Nafaty, A. U. (2006). Pregnancy
outcomes of women with eclampsia in Gombe, Nigeria. Interna-
tional Journal of Gynecology and Obstetrics, 92, 251–252.
23. Jabeen, M., Yakoob, M. Y., Imdad, A., & Bhutta, Z. A. (2011). Impact
of interventions to prevent and manage preeclampsia and eclampsia
on stillbirths. BioMed Central Public Health, 11(Suppl 3), S6.
1198 Matern Child Health J (2013) 17:1191–1198
123
Author's personal copy
